CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to identify genetic biomarkers that predict patient responses to cancer therapies. By using large-scale genetic screens, it seeks to discover new drug targets that are selectively toxic to cancer cells, enhancing personalized treatment options.
While significant progress has been made in the diagnosis and treatment of cancer, several major issues remain unresolved.
First, only a minority of patients respond to most forms of (chemo)therapy.
It is generally believed that this poor responsiveness to drugs has its origin, at least in part, in the molecular heterogeneity of cancer.
This heterogeneity requires the use of biomarkers to stratify patients having seemingly similar tumors according to their likely responses to specific cancer the…
STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
